Skip to Content

Posts tagged with "Cardiovascular Disease"

  • "Me Too" Drugs

    Me Too, Part Two

    As came up in the comments to the previous post, there’s not as much price competition inside a given drug category as you’d think. That’s not because we’re Evil Price Gougers, at least not necessarily. As I was pointed out yesterday, “me-too” type drugs aren’t as equivalent as some people think. The main r… Read More
  • "Me Too" Drugs

    Clinical Trials And What to Do With Them

    Allow me to get a little defensive. If I understand some of the critics of my industry, we spend most of our time making “me-too” ripoff drugs rather than doing something that provides any clinical benefit to patients. And, if I have this right, here’s how we determine efficacy: we run clinical studies until we… Read More
  • Business and Markets

    Pravachol vs. Lipitor Update

    In my March 11 piece below, I mentioned the possibility of Pravachol competing on price with Lipitor. But over at Forbes, Matthew Herper has pointed out that it’s currently more expensive. What BMS is going to do with this drug, I can’t imagine. There’s also a good story in the Newark Star-Ledger about the whole… Read More
  • Business and Markets

    Ignorance Was Bliss

    Just a brief note today about the “PROVE-IT” study that Bristol-Meyers Squibb ran and has now reported on. This was their big shot at Pfizer’s Lipitor, their chance to show that their own statin, Pravachor, was just as good or better. The study was big, it was long, and man, was it expensive. It’s just… Read More
  • Cardiovascular Disease

    Ezetimibe, The Press, and More

    Credit where it’s due! Yesterday I mentioned the original chemist who started the ezetimibe story, but I should note that the drug itself was synthesized by another former colleague of mine, Stuart Rosenblum. He and a host of others developed a huge series of analogs, which built in more acitivity and greater in vivo stability. Read More
  • Cardiovascular Disease

    The Beginning? It’s Right Past the End. . .

    There’s a paper in the latest issue of Science from a team at Schering-Plough that may have tracked down how the company’s cholesterol absorption inhibitor (Zetia, ezetimibe) works. That news really takes me back. It’s been years now, so it won’t do any harm to mention that I used to work there. I had a… Read More
  • Cardiovascular Disease

    Sic Transit Gloria Mundi

    So Entremed is finally giving up on its celebrated peptide drug candidates, angiostatin and endostatin. I’m sorry to see what the company, and its employees have been through, but I’m even sorrier when I think about what cancer patients have been through during this story. Especially those of them who read that (in)famous New York… Read More
  • Cardiovascular Disease

    Trials of Trials

    As I mentioned yesterday, I think the kind of study that compared diuretics with other hypertension medicines was a very good thing. So why don’t we see more of these? There are several reasons. It’s worth thinking about the different levels of testing, and what questions they’re designed to answer. At the first level, you… Read More
  • Cardiovascular Disease

    Cholesterol Lowering, One Way or Another

    Schering-Plough and Merck have won FDA approval for Zetia, their cholesterol absorption inhibitor that I’ve spoken about from time to time. That’s a big step for them, although approval was pretty much assumed. The drug won’t reach its real potential, though, until they can get their combination Zocor/Zetia formulation approved, w… Read More
...151617